Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer.
Yoda S, Soejima K, Hamamoto J, Yasuda H, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Naoki K, Betsuyaku T. Yoda S, et al. Among authors: betsuyaku t. Lung Cancer. 2014 Sep;85(3):366-72. doi: 10.1016/j.lungcan.2014.06.009. Epub 2014 Jun 21. Lung Cancer. 2014. PMID: 25001509
Multiple roles of extracellular fibroblast growth factors in lung cancer cells.
Suzuki T, Yasuda H, Funaishi K, Arai D, Ishioka K, Ohgino K, Tani T, Hamamoto J, Ohashi A, Naoki K, Betsuyaku T, Soejima K. Suzuki T, et al. Among authors: betsuyaku t. Int J Oncol. 2015 Jan;46(1):423-9. doi: 10.3892/ijo.2014.2718. Epub 2014 Oct 21. Int J Oncol. 2015. PMID: 25353145
Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.
Hamamoto J, Soejima K, Naoki K, Yasuda H, Hayashi Y, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Arai D, Ishioka K, Ohgino K, Betsuyaku T. Hamamoto J, et al. Among authors: betsuyaku t. Cancer Sci. 2015 Jan;106(1):34-42. doi: 10.1111/cas.12569. Epub 2014 Dec 8. Cancer Sci. 2015. PMID: 25414083 Free PMC article.
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.
Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K. Hirano T, et al. Among authors: betsuyaku t. Oncotarget. 2015 Nov 17;6(36):38789-803. doi: 10.18632/oncotarget.5887. Oncotarget. 2015. PMID: 26515464 Free PMC article.
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Miyawaki M, Yasuda H, Tani T, Hamamoto J, Arai D, Ishioka K, Ohgino K, Nukaga S, Hirano T, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K. Miyawaki M, et al. Among authors: betsuyaku t. Mol Cancer Res. 2017 Jan;15(1):106-114. doi: 10.1158/1541-7786.MCR-16-0211. Epub 2016 Oct 5. Mol Cancer Res. 2017. PMID: 27707887 Free article.
314 results